In contrast, neither CD68+ ov-TAMs, CD163+ ov-TAMs nor the ratio of CD68+/CD163+ ov-TAMs was associated with age, FIGO stage, residual tumor or chemosensitivity (Table S1). This evidence concerns the gene CD68 and neoplasm.